Management and treatment of *Magnusiomyces capitatus* (*Geotrichum capitatum*) pleural infection in a non-neutropenic patient with posaconazole. A new therapeutic opportunity?

Grazia Brunetti¹, Valeria Visconti¹, Maria Cristina Ghezzi², Sara Mantovani³, Giancarlo Ferretti⁴, Giammarco Raponi²

¹Department of Molecular Medicine; ²Department of Public Health Science and Infectious Disease; ³Department of Thoracic Surgery; ⁴Department of Tropical Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Italy

INTRODUCTION

*Magnusiomyces capitatus* (teleomorph form of *Saprochaete capitata*, previously named *Geotrichum capitatum, Trichosporon capitatum* or *Blastoschizomyces capitatus*) (Arendrup et al., 2014) is a cosmopolitan and ubiquitous fungus, widespread in nature, that can be found in the normal microbial flora colonizing humans. Infections affecting immunocompromised patients are accompanied by a high mortality rate (Saghrouni et al., 2012; Bonini et al., 2008; Trabelsi et al., 2015), but data in the immunocompetent patient are rare (Miglietta et al., 2015). Diagnosing the infection may be difficult, especially in the early stages of the disease, and cultural procedures may fail to reveal the fungus in clinical samples. Amphotericin B alone or in combination with flucytosine is the mainstay of therapy for this infection. This study describes the case of *M. capitatus* pleural infection in a non-neutropenic patient successfully treated with oral posaconazole.

CASE REPORT

A 75-year-old female dyslipidemic hypertensive patient had a history of invasive carcinomas as follows: in 1987 bilateral ductal carcinoma of the breast (pT1, pN0, M0) complicated in 2009 with cutaneous metastasis; and right lung adenocarcinoma (pT2a N0) treated with lower lobectomy and lymphadenectomy in 2012. In January 2015 she was admitted to Umberto I University Hospital in Rome (Italy) for asthenia, productive cough and low-grade fever (<37.5°C) non-responsive to lengthy antibiotic therapy. On admission, laboratory examinations showed moderate leukocytosis, and elevated CRP (Table 1). Under observation, the patient was treated with nebulized colistin (10⁶ units, twice daily) and antipyretics as needed. On day 15, fever peaked to 38.8°C and therefore a contrast CT total body and a bronchoalveolar lavage (BAL) were performed. The CT disclosed a fluid abscess in the posterior right side of the pleural space along with two fistulae (Fig. 1). BAL showed negative cytology for cancer cells, subsequently confirmed by pulmonary biopsy. The levels of galactomannan (GM) antigen, as detected in the BAL by ELISA test (Platelia® Aspergillus, BioRad Italy), resulted positive (0.7 U/mL). BAL culture revealed the growth of 10⁴ CFU/mL *Enterococcus faecalis*. Rifampin therapy was initiated (600 mg/die i.v. for ten days). On day 26 due to the persistence of low-grade fever, leukocytosis and elevated inflammatory markers (Table 1), the abscess was broken by fibroscopic and DYNA-CT guide. The drainage material was sent to the microbiology laboratory where the gram staining revealed septate mycelial filaments and unbranched arthrospores. Culture was performed and *M. capitatus* pleural infection, as identified by MALDI-TOF, positivity for galactomannan antigen in the BAL fluid, and successfully treated with oral posaconazole in single therapy.

SUMMARY

*Magnusiomyces capitatus* may cause uncommon yet severe infections, especially in patients with hematologic disorders. Diagnosis may be difficult and time-consuming and newer approaches are required including the MALDI-TOF technique implemented with the detection of fungal antigens in the body fluids. The recommended treatment includes amphotericin B alone or in combination with flucytosine. We describe a case of a non-neutropenic patient with *M. capitatus* pleural infection, as identified by MALDI-TOF, positivity for galactomannan antigen in the BAL fluid, and successfully treated with oral posaconazole in single therapy.
the fungus. In fact, as shown in the species dendrogram gained from our database (5627 entries, Fig. 2), there is enough distance between species to discriminate between M. capitatus, Geotrichum candidum and Saprochaete clavata. The susceptibility test (Sensititre YeastOne YO10, Thermo Fisher Scientific, USA) disclosed MIC values of 0.5 µg/mL for posaconazole, 0.12 µg/mL for voriconazole, 1 µg/mL for amphotericin B, 8 µg/mL for fluconazole and 8 µg/mL 5-flucytosine. On the basis of microorganism identification, therapy was immediately implemented with amphotericin B (Ambisome 250 mg/die i.v). However, due to an immediate appearance of a cutaneous rush reaction, antimycotic therapy was shifted to oral posaconazole (400 mg B.I.D., delayed-release tablets for ten days). With the new antifungal therapy her fever curve continuously decreased until complete remission. Similarly, leukocytosis, CRP and galactomannan antigen remitted after 5 days of antimycotic treatment (Table 1). At 60th day of hospitalization, a one-way Zephyr 5.5 valve was placed on the larger fistula, and fibrin glue was instilled on the smaller fistula. Chest CT scan showed fistulas and abscess resolution.

**DISCUSSION**

*M. capitatus* is predominantly found in Europe as an opportunistic pathogen mainly observed in immune-compromised patients. Risk factors for the development of infections are immune suppression, the destruction of the normal microbial flora due to the use of broad spectrum antibiotics, cytotoxic chemotherapy, catheterization, and neutropenia (less than 100/mm³) (Girmenia et al., 2005). In neutropenic patients *Geotrichum* species may cause both invasive disseminated and bloodstream infections (77%) (Bonini et al., 2008). Nevertheless, gastrointestinal, urinary and cutaneous involvement have been reported (Ozkaya-Parlakay et al., 2012), and pulmonary association is common in *M. capitatus* sepsis (Girmenia et al., 2005, Martino et al., 1990). Local infections have been rarely observed in the immunocompetent patients (Ozkaya-Parlakay et al., 2012, Subramanya Supram et al., 2015). In this report we describe the first case of pleural infection in a non-hematologic patient, successfully treated with oral posaconazole.

Diagnosis of *M. capitatus* infections may be difficult and the data reported in the literature on the identification of *M. capitatus* are conflicting. Desnos-Ollivier et al. showed misidentification between species of *S. clavata, M. capitatus* and *Galactomyces candidus* (Desnos-Ollivier et al., 2014). In their study, performed by sequencing the internal transcribed spacer regions, the nucleotide sequences of *S. clavata* and *M. capitatus* were either misidentified or too short (163 bp). However, other studies proved that MALDI-TOF MS is an excellent diagnostic tool to provide reliable identification of most (98%) of the tested strains to the species level, with good discriminatory power (Kolecka et al., 2013). Additionally, the detection of serum galactomannan (GM) in the diagnosis of *M. capitatus* was reported in the case of disseminated infection (Bonini et al., 2008; Ozkaya-Parlakay et al., 2012; Giacchino et al., 2006). To our knowledge, no sound studies reported that GM could be detected in the BAL fluid during a pleural infection sustained by *M. capitatus*, as was the case of our

![Figure 1](image1.png)

**Figure 1** - CT total body: abscess in the posterior right side of the pleural space with the insertion of the drainage tube (arrow).

![Figure 2](image2.png)

**Figure 2** - MALDI-TOF Biotyper OC 3.1 dendrogram. Distant levels between *M. capitatus, Geotrichum candidum* and *Saprochaete clavata* allow species discrimination.
patient. Our finding was supported by the observation that the measurement of GM antigen in the BAL seems to be a better diagnostic tool in localized infections than in serum (Kono et al., 2013). However, our observation must be interpreted with caution, since GM indices between 0.5 and 1 in BAL samples, especially from non-immunocompromised patients, might represent false positive results. Several studies reported false positive results of GM detection in patients receiving beta lactam antibiotics, including carbapenems (Viscoli et al., 2004; Boonsarrngsuk et al., 2010). However, our patient was treated with rifampin, and the negativity of the GM antigen after antifungal therapy excluded a false positive result. Nowadays treatment of M. capitatus infection remains debatable (Arendrup et al., 2014, Saghrouni et al., 2012). Amphotericin B, alone or in combination with fluconosine (Martino et al., 1998, Schiemann et al., 1998, D’Antonio et al., 1996), seems to be the most effective regimen. *In vitro* the broad spectrum fungicides such as voriconazole, posaconazole and ravuconazole seemed to be effective in the treatment of invasive fungal infections (Arendrup et al., 2014, Schiemann et al., 1998, Blau et al., 2000, Granier, 2000). Girmenia et al. reported a high activity of amphotericin B and voriconazole against *M. capitatus* and the poor susceptibility of some strains to fluconosine, fluconazole and itraconazole. Our patient had an adverse reaction to amphotericin B therapy and treatment was shifted within 24 h to oral posaconazole. Posaconazole treatment might be an excellent therapeutic opportunity.

**Note.** Due to the clinical information contained in this article, informed consent was gained from the patient. The research has complied with all relevant international guidelines and institutional policies.

**Potential conflict of interest.** All authors: No potential conflict.

**References**


